Oral Quercetin Supplementation Enhances Adiponectin Receptor
Transcript Expression in Polycystic Ovary Syndrome Patients: A
Randomized Placebo-Controlled Double-Blind Clinical Trial
Polycystic ovary syndrome (PCOS), an ovarian-pituitary axis androgen disorder, is a common endocrine disease in women. Obesity-induced androgenesis and imbalance of adipokine secretion may lead to some metabolic features of PCOS. The beneficial effects of polyphenolic compounds such as quercetin have been reported, however, the underlying molecular mechanism is not entirely understood. In the present study, we investigated the effect of quercetin supplementation on the expression of adiponectin receptors at the transcript level in peripheral blood mononuclear cells (PBMC) samples of PCOS patients.
Materials and Methods
In this randomized clinical trial, 84 PCOS subjects were randomly assigned to two groups; the
treatment group received 1 g quercetin (two 500 mg capsules) daily for 12 weeks and the control group received placebo.
To examine the effect of quercetin supplementation on PCOS patients in addition to biochemical and anthropometric
assessments, the expression of
Oral quercetin supplementation significantly increased
Oral quercetin supplementation improves the metabolic features of PCOS patients by upregulating the expression of adiponectin receptors and AMPK (Registration Number: IRCT2013112515536N1).